Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787.
BMJ Open Diabetes Res Care. 2021.
PMID: 33441417
Free PMC article.